Zobrazeno 1 - 10
of 52
pro vyhledávání: '"35"'
Autor:
Mónica Carbajales, Rubén Fernández, Beatriz Fernández, Yoar Labeaga, Rubén Pampín, Belén Rodríguez
Publikováno v:
Journal of Oncology Pharmacy Practice. 26:549-555
BackgroundWe describe the feasibility and safety of an oral administration schedule of hydration, alkalinization and leucovorin rescue with an ambulatory high-dose methotrexate regimen.MethodsSingle-centre prospective observational study conducted wi
Publikováno v:
Technology in Cancer Research & Treatment
Technology in Cancer Research & Treatment, Vol 20 (2021)
Technology in Cancer Research & Treatment, Vol 20 (2021)
Objective: To investigate the characteristics of central nervous system (CNS) involvement in children with non-Hodgkin’s lymphoma (NHL) and the value of flow cytometry (FC) in the diagnosis of CNS disease in pediatric NHL. Methods: The data of 56 n
Autor:
Francisco J. Vizoso, Quintela I, Antonio M. Merino, Serra C, Luis O. González, A Baltasar, Fernández R
Publikováno v:
The International Journal of Biological Markers. 16:240-244
Background The aim of this study was to evaluate the pepsinogen C expression in malignant cutaneous melanomas and analyze its possible relationship to clinical and pathological parameters. Pepsinogen C is an aspartyl proteinase primarily involved in
Publikováno v:
Scopus-Elsevier
Objective The aim of this phase I study was to find the maximum tolerated dose of weekly docetaxel in association with estramustine in hormone-refractory prostate cancer. Methods Eleven patients with hormone-refractory prostate cancer were treated wi
Publikováno v:
Journal of Oncology Pharmacy Practice. 26:861-865
IntroductionDespite first-line approval in metastatic renal cell carcinoma (mRCC), the tyrosine kinase inhibitor cabozantinib is associated with frequent treatment-limiting side effects. Dose reductions in published trials of the drug and in clinical
Autor:
Moez Elloumi, Ben Mahmoud Lobna, Nouha Bouayed, M. Mdhaffar, Tarek Rebai, Fakher Frikha, Rim Frikha, Imen Frikha
Publikováno v:
Journal of Oncology Pharmacy Practice. 25:1182-1186
Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms, mainly the C677T, have been implicated as risk factors for several cancers as the acute lymphoblastic leukemia (ALL). In addition, a potential effect of such variant on the efficacy of m
Autor:
Seung-Ill Park, Junhee Han, Kanghoon Lee, Hyeong Ryul Kim, Se Hoon Choi, Dong Kwan Kim, Yong-Hee Kim
Publikováno v:
Asian Cardiovascular and Thoracic Annals. 25:623-629
Background The aim of this retrospective study was to review recurrence patterns of stage I non-small-cell lung cancer and identify prognostic factors for post-recurrence survival. Methods Among 940 patients with pathological stage I non-small-cell l
Publikováno v:
Journal of Oncology Pharmacy Practice. 24:604-608
Purpose Pegfilgrastim is indicated to reduce the risk of febrile neutropenia. As a cost-savings initiative, Pegfilgrastim Process Guidelines were developed and implemented at a large, academic teaching institution to improve appropriate use of pegfil
Publikováno v:
Integrative Cancer Therapies, Vol 17 (2018)
Integrative Cancer Therapies
Integrative Cancer Therapies
Objective. Numerous studies have investigated the efficacy of mindfulness meditation (MM) in managing quality of life (QoL) in cancer populations, yet only a few have studied the Asian population. The aim of this exploratory study is to evaluate the
Autor:
Rodrig Marculescu, Barbara Obermayer-Pietsch, Michael Trauner, Vanessa Stadlbauer, P Munda, Magdalena Eilenberg, Rudolf E Stauber, Emina Halilbasic, Judith Stift, Walter Spindelboeck, A Posch, Carolin Lackner, Katharina Staufer, Gerhard Prager
BACKGROUND: In nonalcoholic fatty liver disease (NAFLD), advanced fibrosis has been identified as an important prognostic factor with increased liver-related mortality and treatment need. Due to the high prevalence of NAFLD, noninvasive risk stratifi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e22fd31f09b59dbf2911d64383614f56
https://europepmc.org/articles/PMC6794685/
https://europepmc.org/articles/PMC6794685/